Allogene Therapeutics, Inc. (ALLO)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 487.41M |
| Enterprise value | 133.84M |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 4.72k |
| Price/book (mrq) | 0.95 |
| Enterprise value/revenue | 1.41k |
| Enterprise value/EBITDA | -0.45 |
Trading information
Stock price history
| Beta (5Y monthly) | 0.80 |
| 52-week change 3 | -47.33% |
| S&P500 52-week change 3 | 21.08% |
| 52-week high 3 | 6.8900 |
| 52-week low 3 | 2.2300 |
| 50-day moving average 3 | 4.3694 |
| 200-day moving average 3 | 3.7391 |
Share statistics
| Avg vol (3-month) 3 | 2.3M |
| Avg vol (10-day) 3 | 1.99M |
| Shares outstanding 5 | 170.72M |
| Implied shares outstanding 6 | 170.72M |
| Float 8 | 111.02M |
| % held by insiders 1 | 22.21% |
| % held by institutions 1 | 72.91% |
| Shares short (15 Apr 2024) 4 | 31.36M |
| Short ratio (15 Apr 2024) 4 | 13.77 |
| Short % of float (15 Apr 2024) 4 | 28.54% |
| Short % of shares outstanding (15 Apr 2024) 4 | 18.40% |
| Shares short (prior month 15 Mar 2024) 4 | 27.75M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | N/A |
| Last split date 3 | N/A |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Dec 2023 |
Profitability
| Profit margin | 0.00% |
| Operating margin (ttm) | 163,475.00% |
Management effectiveness
| Return on assets (ttm) | -26.84% |
| Return on equity (ttm) | -55.51% |
Income statement
| Revenue (ttm) | 95k |
| Revenue per share (ttm) | 0.00 |
| Quarterly revenue growth (yoy) | N/A |
| Gross profit (ttm) | N/A |
| EBITDA | -300.29M |
| Net income avi to common (ttm) | -327.26M |
| Diluted EPS (ttm) | -2.0900 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 448.7M |
| Total cash per share (mrq) | 2.65 |
| Total debt (mrq) | 95.12M |
| Total debt/equity (mrq) | 18.57% |
| Current ratio (mrq) | 12.38 |
| Book value per share (mrq) | 3.04 |
Cash flow statement
| Operating cash flow (ttm) | -237.73M |
| Levered free cash flow (ttm) | -134.26M |
© 2024 Yahoo. All rights reserved.